Enterprise DNS filtering engineered for pharmaceutical companies. Protect proprietary drug formulations, secure clinical trial data, achieve FDA 21 CFR Part 11 compliance, and stop corporate espionage campaigns targeting your research pipeline.
Pharmaceutical companies invest billions in R&D over decade-long development cycles. A single data breach exposing proprietary molecular structures, clinical trial results, or FDA submission documents can erase years of competitive advantage and billions in shareholder value overnight.
Nation-state actors and organized criminal groups specifically target pharmaceutical IP. During the COVID-19 pandemic, cyberattacks against pharma companies surged by over 600%, and the web landscape has only intensified as biologics, gene therapies, and mRNA platforms represent even higher-value targets.
Our intelligence team tracks bad actors that specifically target pharmaceutical and biotech companies. We maintain curated feeds covering APT groups known for IP theft campaigns against pharma, including those linked to state-sponsored programs seeking to shortcut their own drug development through stolen research.
The 90-million-domain database includes categorization for pharmaceutical-specific content risks: counterfeit drug distribution networks, unauthorized clinical data sharing platforms, competitor intelligence gathering domains, and social engineering infrastructure designed to target scientists and research directors.
We also track domains impersonating legitimate pharma supply chain partners, CROs, and regulatory bodies used in spear-restricted content campaigns that seek to harvest credentials for electronic lab notebooks, LIMS systems, and regulatory submission portals.
Protecting the world's most valuable intellectual property requires specialized security
Drug formulations, synthesis routes, and biological sequences represent years of investment. Sophisticated bad actors use DNS-based exfiltration to slowly siphon molecular data from research networks, encoding proprietary information within DNS query strings that bypass traditional DLP tools.
Manipulated clinical trial data can lead to dangerous drugs reaching patients or effective treatments being delayed. DNS filtering prevents unauthorized access to clinical data management systems and blocks communications to domains associated with data manipulation campaigns.
Electronic records used in FDA submissions must maintain integrity, authenticity, and confidentiality. DNS filtering adds a critical network-level control that demonstrates due diligence in protecting electronic records systems from unauthorized access and data tampering.
Modern laboratories rely on internet-connected instruments that communicate with vendor clouds for calibration, data analysis, and maintenance. Each connected instrument creates a DNS-resolvable attack vector that could compromise research data or introduce malicious firmware.
Pharmaceutical companies share sensitive data with contract research organizations, manufacturing partners, and distribution networks. DNS filtering ensures that partner access is restricted to approved resources and prevents compromised partner credentials from enabling data theft.
Disgruntled employees or recruited insiders may attempt to exfiltrate proprietary data to competitors or foreign entities. DNS filtering detects and blocks unusual domain access patterns, file-sharing platform usage, and encrypted tunnel establishment that indicate insider data theft in progress.
Protecting every stage of the drug development lifecycle
Segment DNS resolution for research, manufacturing, and corporate networks. Prevent lateral movement between environments with distinct filtering policies per network zone and department.
Advanced detection of DNS tunneling, encoding schemes, and slow-drip exfiltration techniques. Identify data hidden in DNS query patterns, TXT records, and CNAME chains used by advanced bad actors.
Automated generation of 21 CFR Part 11 compliance evidence including access control logs, system integrity records, and audit trails demonstrating electronic records protection measures.
Strict DNS allowlists for connected lab equipment. Only approved vendor domains, calibration services, and software update servers are accessible from instrument networks, blocking all unauthorized communications.
Uniform filtering policies across research sites, manufacturing facilities, and offices worldwide. Centralized policy management ensures consistent IP protection regardless of geographic location or local network architecture.
Real-time notifications when DNS queries match known pharma-targeting APT infrastructure. Integrate with SIEM platforms for correlation with other classification indicators across your security stack.
Real-world applications protecting the pharmaceutical research pipeline
A top-20 pharmaceutical company deployed DNS filtering across their drug discovery division to prevent exfiltration of proprietary compound libraries. The system detected and blocked DNS tunneling attempts from a compromised high-performance computing cluster that was encoding molecular structure data in DNS queries destined for a foreign server.
A global CRO implemented our DNS filtering to protect Phase III clinical trial data across 150 research sites worldwide. The centralized policy engine ensures consistent data protection standards at every site, while per-site customization allows local regulatory requirements to be met without compromising the global security posture.
A biologics manufacturer secured their production facility networks with DNS filtering that restricts connected bioreactor control systems to approved vendor domains only. The allowlist approach prevents any unauthorized internet communication from manufacturing equipment, protecting proprietary production processes and batch records from theft.
A mid-size pharma company used DNS filtering to create a hardened network zone for FDA submission preparation. Only domains associated with the FDA eCTD gateway, approved document management systems, and internal collaboration tools are accessible from the submission network, preventing any possibility of submission data leakage during the review process.
Deploy DNS filtering that understands pharma content risks and meets FDA compliance requirements
Start Protecting Your IP Today